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Myocardial contrast echocardiography, has been found to
be a safe and useful technique for evaluating relative
changes in myocardial perfuaom and delineating area at
risk. Although earlier contrast agents required direct de .
livery into the coronary arteries or aortic root, a new
echocardlographic contrast agent, sonkated albumin in! .
creephmm (Mbunes), has hen found to man the pomo-
mary circulation
in experimental models.
To determine the
safety
and preliminary eBicacy , of
latravnoas injections of Albunn la humans, 71 patients at
three Independent medical imB4lioes underwent two .
dimembmal echoardlogaphic nomination before, during
and alter the administration of three Intravenous doses of
Album, ranging from 0 .01 to 0.12aft body weight. All
patients provided a complete ldstory and underwent phys-
teal led narologic enamiaato and laboratory and elec.
traardiogaphlc evaluation before the Injection ; all oval.
nations (except for the history)
were repeated at 2 h and 3
Contrast echocardiography has evolved as a diagnostic
technique since the early report of Gramiak and Shah (1)
describing a contrast effect after injection of indocyanine
green dye. This contrast technique can be used to detect
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days after the injections of Albaaea . The
efficacy
of the
Injections was qualitatively assessed by two independent
blinded observers using a grading system of 0 to +3, with O
Indicating an absence of contrast effect ad +3 indicating
Nil oparilcatfou of the cavities examined .
AB Injections were well tolerated and no srnns sign
effects were noted in any of the
patents.
Irrespective of
dean group, a cavity opaetfcatiow ze+2 was seen in the right
ventricle In 212 (88%) of 240 Infectious and in the left
ventricle to 151 (63%) of 240 injection m judged by the
independent observers. The degree of ventricular cavity
opadfcalion appeared to be dose and concentration re-
nted. In condo", then first maldanter clnical study of
Mhunex desaomteatee that the contrast agent Is safe when
administered intravenously and achieve
; sipitkant
tranpnhaooary, passage In a majority of paBnls .
(J Ain Call Ce.rdie11990;16:31624)
valvular regurgitation (2), identify retrial and ventricular
cavities (3), assess septa) defects and complex congenital
heart disease (4) and measure cardiac output
(5); more
recently, it has been used intraoperatively to evaluate
repair of cardiac valves (6) and myocardial perfusion (7) . A
variety of contrast agents employed include agitated in-
docyanine green (1), saline or dextrose solution (8), hand.
agitated Renografin-76 (meglumine diatrixoate) (9), various
sonicated solutions
(10) . gelatin microspheres (11),
albumin-
coated bubbles ( ;2),
hydrogen peroxide (13) and lipid emus
sions (4).
Specifically, contrast echocardiography has been used
after intacoronary , or intraaortic injections to assess myo-
cardial perfusion defects
(9,13), area at risk (14,15), coronary
blood flow (16-18) and coronary flow reserve (19,20). How.
ever, to accurately assess perfusion, a contrast agent should
meet several criteria. The agent should be biologically inert
0735-1097,9wr3.56
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(without systemic hemodynamic effects) and should not alter
native coronary blood flow (21). The microbubbles that
serve as the ultrasound contrast agent should be of equiva-
lent size and distribution and permit unimpeded microvas-
cular flow (22,23). The microbubbles should exhibit physio-
logic transit time, yet the contrast effect should be sustained
long enough to permit adequate imaging over time. Previous
contrast agents have not been tested o1 generally did not
meet these criteria. Several reported agents are hyperosmo-
tar and alter coronary blood flow or systemic blood pressure
(20,24) and left ventricular contractility (25,26) . Hand-
agitated solutions and hydrogen peroxide provide intense
ultrasound backscatter through the production of large mi-
crobubbles (10), but these microbubbles have been shown
(22,27) to impede capillary flow, resulting in prolonged
transit times. However, previous contrast agents have been
observed (11,12,28-3l) to pass successfully through the
pulmonary circulation in sufficient concentration to opacify
the left ventricle after intravenous injection . Thus, it is
feasible to pursue the goal of establishing a reproducible
transpulmonary ultrasound agent .
Recently (32-34) sonicated albumin microspheres have
been evaluated as an echocardiographic contrast agent. In
experimental studies (35), sonicated albumin solutions have
been shown to not alter hemodynamics, coronary blood flow
or left ventricular contractility . A preliminary clinical inves-
tigation (34) using a commercially prepared sonicated albu-
min contrast agent (Albunex) containing stable air-filled
microspheres of known sizes and concentration evaluated
the safety and efficacy of performing intravenous studies in
patients.
This investigation was designed as a multicenter clinical
study to assess the safety of using intravenous injections of
Albunex in patients and to systematically evaluate the ability
of this agent to opacify the left-sided cardiac chambers after
passing through the pulmonary circulation . The quality of
the contrast effect obtained with different concentrations of
the commercially prepared Albunex microspheres was also
investigated .
Methods
The study was carried out in three institutions: the
University of Chicago, Chicago, Illinois ; Baylor College of
Medicine, Houston, Texas and the Thoraxcenter, Erasmus
University, Rotterdam, The Netherlands
. The protocols
used at the University of Chicago and Baylor College of
Medicine were identical and are collectively referred to
as protocol 1. Protocol I included mildly hypertensive
patients who received serial intravenous injections of in-
creasing volumes of the contrast agent, containing the
same concentrations of microspheres
. The protocol at the
Thoraxcenter (protocol 2) involved healthy (normotensive)
patients who received two different concentrations of the
FEINSTEIN ET AL .
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air-filled microspheres
. Specific details of the protocols
involved in this multicenter study are outlined next. (Un-
less specifically indicated, protocols I and 2 were identical .)
The study protocols were approved by the institutional
review boards for human studies of the three participating
institutions .
Study patients. Protocol 1 . Patients who met the follow-
ing criteria were asked !o enroll in the study : 1) age between
18 and 65 years inclusive; 2) male gender or, if female, with
no child-bearing potential ; and 3) history of mild hyper-
tension (blood pressure <200 mm Hg systolic, 90 to 109
mm Hg diastolic) controlled on a medical regimen (blood
pressure <_165185 mm Hg at supine rest) . Exclusion of
women of child-bearing age conformed with the usual and
customary practice of excluding this group from research
dn,g therapy.
Patients were excluded from the study if they had any of
the following: 1) previous transient ischemic attacks, cere-
bral vascular accident, myocardial infarction or congestive
heart failure as documented by medical history or current
physical examination; 2) the presence of a known right orleft
heart shunt, cardiac murmur or valvular disease as docu-
mented by previous medical examination or diagnostic stud-
ies ; 3) a history of chronic obstructive pulmonary disease,
asthma or other known lung disease as assessed by previous
or current medical examination or pulmonary diagnostic
studies ; 4) a history of blood product allergy ; 5) acute or
unstable medical condition requiring hospitalization ; 6) Iife-
threatening arrhythmia or heart block of greater than first
degree as assessed by a previous or current electrocardio-
gram (ECG) ; 7) mental incompetence as assessed by history
of Alzheimee s disease, mental retardation or organic brain
disease documented in the patient's medical history or
discovered during the current examination ; or 9) failure to
provide signed informed consent .
Protocol 2 (horaxcenter). Patients in protocol 2 were
healthy volunteers (that is, not hypertensive) . The inclusion
and exclusion criteria were otherwise identical to those in
protocol 1 .
Basic study design. Protocol 1. The study design con-
sisted of five periods : 1) prestudy, 2) preir&ction baseline, 3)
testing, 4) 2 h follow-up, and 5) 3 day follow-up. During the
prestudy period, within 7 days before injection, the patient's
demographic and medical history data were collected
. In
addition, a physical and neurologic examination and lahma-
tory evaluation including blood chemistry values, prothrom-
bin time, complete blood count and urinalysis was per-
formed during the prestudy period, immediately before
injection (preinjection baseline), 2 h after injection and 3
days after injection. The testing period consisted of five
intravenous injections : two of 5% serum albumin (control)
followed by three of Albunex. All injections were performed
manually approximately 5 min apart to enable vital signs to
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be measured after each injection and to assure clearance of
the remaining contrast effect from the previous injection
.
Patients were enrolled in three groups of 10 patients .
Each group received a different range of Albunex volumes
containing 5 x 100 microspheres/ml. The first group of t0
patients received volumes of 0.01, 0
.02 and 0
.04 mUkg, the
second 10 patients received volumes of 0.04, 0.06 and 0 .08
mllkgand the third 10 patients received volumes of0 .08, 0 . 10
and 0 .12 ml/kg All patients received control volumes of 0 .5
and 1 .0 ml of 5% serum albumin (PPG, Cutter), respectively,
which served as a control medium for the Albunex contrast
ultrasound agent .
Protocol 2
.
The basic study design of protocol 2 differed
from that of protocol I in that during the testing period,
subjects received one injection of I ml of 5% human serum
albumin followed by six injections of Albunex. The six
injections consisted of administering three equal volumes
(0.01, 0 .02 and 0.04 ml/kg) of Albunex solutions that con-
tained two different microsphere concentrations : 5 x 100
microsphereslnd Dow concentration, same as in protocol 1)
and 8 x 100 microspheres/ml (high concentration). The order
of the injections was the same in each study : injection I = 1
ml of 5% human albumin; injection 2 = 0.01 ml/kg of
Albunex (low concentration); injection 3 = 0
.01 mIkg of
Albunex (high concentration); injection 4 = 0 .02 mUkg of
Albunex (low concentration); injection 5 = 0.02 rrAg of
Albunex (high concentration); injection 6 = 0 .04 mIkg of
Albunex Dow concentration) ; and injection 7 - 0 .04 mI/kg of
Albunex (high concentration) .
Administration procedure. A standard idtravenous infu-
sion containing either 5% dextrose in water oro .45% or0
.9%
sodium chloride from the left or right antecubital vein was
performed using an 18 gauge (three patients protocol I only)
or a 20 gauge angiocatheter connected to a three-way stop-
cock. After obtaining a satisfactory precontrast echocardio-
graphic image in the apical four chamber view, control
injections of 5% serum albumin followed by injections of
Albunex were performed .
Two-dimensional echoardlegraphlc examination and can .
traet evaluation
. The following commercially available ultra-
sound systems were used by the investigators : General
Electric Pass H, General Electric RT5000, Advanced Tech-
nology Laboratories MK 600, Hewlett-Packard 77020AC or
Toshiba SSH/160A . All were equipped with either a 2 .5, 3 .5
or
S MHz transducer. Volunteers were examined in either
the supine or lateral decubitus position . Apical four chamber
views were obtained, and gain, reject and intensity settings
were optimized at the beginning of each study and were not
changed during the study . Imaging was begun just before
each injection and continued for 2 to 3 min after each
injection to assure clearance of the contrast agent . Images
were recorded on 0 .5 in . (1
.27 cm) VHS videotape and were
later analyzed by the independent blinded observers using
the described grading system
.
(ACC Vol . IS . No. 2
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FSgureI . Histogram ofatepresealativesample ofthecontrast agent
demonstrating the size and frequency distribution of the micro-
spheres
. The average diameter is 4µm .
Safety and efficacy .continue.
Safety was evaluated by
observing the patients for the development of adverse signs
and symptoms during the testing and follow-up periods and
by laboratory evaluations performed during the testing pe-
riod . Blood pressure, pulse rate, respiratory rate, tempera-
ture and laboratory variables were measured before the
testing period and at both 2 h and 3 days after testing.
Additional measurements of blood pressure, heart rate and
respiratory rate were performed before each injection and
after the final injection. Each patient's neurologic status was
assessed throughout the testing period . Subjective com-
plaints, changes in mentation and body tone and respiratory
problems were recorded as adverse events .
Quality of contrast effect was assessed
by observing the
magnitude of contrast in the cardiac chambers and was
evaluated by opaeifieation grades of 0 (no contrast), +1
(trace), +2 (intermediate) and +3 (full opaeification) . Two
independent blinded observers (P.M.S . and W.F.A.) at
institutions not involved in the clinical trials reviewed all
injections in a random order
. For the efficacy gradings, the
blinded observers were not told the agent (control medium
versus Albunex), volume or order of injection
. The grades
assigned by the blinded observers were averaged and re-
ported.
Tai materials. Albunex is composed of sonicated human
serum albumin in a sterile, nonpyrogenic aqueous solution .
The sonication process is performed by the manufacturer
(Molecular Biosystems) on the albumin (human) 5% solu-
tion, biologic approved by the Food and Drug Administra-
tion . In the process, air-filled albumin mierospheres are
formed, having an average diameter of 4 pan (Fig . 1).
Stalk" analpah
. Data were entered into a data base
and checked by double entry or manual inspection
. Analysis
of variance was used to detect changes in vital signs or
laboratory data between prestudy, preinjection baseline test-
ing and 2 h and 3 day follow-up periods . Changes were
ton
so
~ GO
4a
1111xo
fA Il xA 2a 3 .0 41 eA r.0 0.2 11414.6183 23.1'
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Table 1. Demographic Data From 71 Patients
considered significant at p s 0.05 . Data are expressed as
mean values ± I SD.
Results
Patient demographic data (Table 1)
.
A total of 60 patients
were recruited in protocol I and an additional I I patients in
protocol 2 . The University of Chicago group I contained
only men who were significantly heavier (91 .6 ± 14.0 kg)
than patients in group 111(78.1 ± 14 .0 kg, p < 0 .05), which
was composed primarily of women, The three groups did not
differ significantly in age or height . The patients in the Baylor
College of Medicine group I were significantly younger than
patients in group fI (48.3 t 10.7 versus 57.6 ± 7 .8 years, p <
0.05), but the two groups did not differ in regard to height or
weight, Comparing the University of Chicago patients with
the Baylor College of Medicine patients, the only significant
difference was the age of the patients in group
11(39
.5 ± 14
.7
versus 57.6 ± 7.8 years, p < 0.01)
.
The Thoraxcenter pa-
tients were younger and taller than the patients at the two
other institutions (p < 0 .001 and <0 .05 . respectively). They
were also lighter than the group I patients at the other
institutions (p < 0 .02).
Values are expressed as mean values ± I SD. Hyptnensive patients were studied under protocol I and
normatensivepollensunderprotocol2
.Groups1.11and111indicate .Albuneavolumes(with lof0.01,0.02and0.04
(group 1)
. 0.04. 0
.06 and 0.08 (group 11) and 0.08 .0.10 and 0 .12 (group 111)
.
Table 2. Summary of Vital Signs in the 60 Hypertensive Patients in Protocol I
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Safety Evaluation
Vital signs ad physical and laboratory data (Tables 2 sod
3).
Significant changes in pulse rate, respiratory rate and
temperature were detected by analysis of variance when
comparing the 2 h postinjection period with the 3 day
postinjection period in patients studied with protocol 1 .
These data were adjusted for baseline values (prestudy
values)
. However, these adjustments were minor and not
thought to be
of clinical significance.
A statistically significant change in systolic blood pres-
sure was seen in the protocol 2 patients (Table 3). How-
ever, this finding was not considered to be of clinical
significance
.
Adverse reactions. Adverse reactions were minor and
infrequent. These included a feeling of matting on the
surface of the eye not accompanied by objective visual
deficits in one patient, unusual taste sensation after injec-
tions in two patients, lightheadedness on standing at the
conclusion
of the 2 h
study in two patients and erythema
near the intravenous catheter site in one patient . No new or
significant neurologic deficits or physical findings were noted
during the 2 h or 3 day follow-up examinations .
'Tbe analysis of variance (ANOVA) was determined fm the 2 h twstiniatiou values as compared with the 3 day
postinjedion values (adjusted for baseline or prestudy values). Values art eapesred as mm values x I SD.
DBP = diastolic Word prerute; HR = bean rate
: Resp = respiratory
; SBP -
systolic blood pressure ; Temp =
ampemwre.
No. Before Study
2 h After
lejeclion
3 Days After
hyection
pValue
Sap (mm Hg) 60 137.5 ± 15 .0
140
.2±112 1361
NS
DBP (mm Hg) 60 88 .0 x 9.7
97
.8x75 89
.5x9
.4
NS
HR(bealslwm(
60
71.9
± 103 70.6 3 79' 74.4 310.0' <0.006
Resp sate Iborull s+mirt
60 17.1 3 2 .5 17.0 0 28' 15.8 x 2.3' <0.005
Temp (°C) 57 36.67 ± 032 36.59 *_ 0
.36'
36.78 x 0.31' <1004
No. Age (yn Height Icm) Weight full
Untversily of Chicago (protocol I)
Group 1 10 40,D t 10.7 175 ± 11
91 .6 ± 14.0
Group 11 10 39 .5_14.7
180x7 00 .1±19.0
Group III ID 49.2 x 10
.9 165 x 13 78.1 x 14.0
Baylor College of Medicine (protocol I )
Group 1 10 40.3_10.7 174 t5 94.4316.5
Group 11 10 57.6x7.8 17637 95.1±17.0
Group 111 10 48.5x94 175x10 77.0 •_ 125
'fhotaaceoter(protocoi21
Group 1 I I 22.5x20 18636 78.9x8 .4
320
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Table 3 . Summary of Vital Signs in the I I Normotensive Patients
in protocol 2
Values are expressed as mean values ± 1 So. p values were determined
by analysis of variance (ANOVA). Abbreviations
as
in Table 2.
No signfcant differences in the laboratory variables studied
during the initial examination and at 2 h and 3 days after the
study were detected by analysis of variarrce for the patients at
any of the institutions . No significant ECG changes other than
minor nonspecific ST-T wave abnormalities were noted .
Quality of Contrast Effect
Protocol I (Table 4) . Figure 2 demonstrates sequential
opacification of the right and left ventricles after a single
injection of 5 .9 ml of Albunex . As expected, increasing
volumes of Albunex resulted in higher opacification grades
Table 4. Percent of 60 Hypertensive Patients in Protocol I
Having *Grade +2 Cavity Gpacification
'Note that only 9 of the 10 patients in Group
I from the University of
Chicago were entered into the efficacy analysis because of technical difli-
cubles encountered during the videotape recording of Patent 3 . Data are
eapressed as
the mean values determined by two blinded observers . See Table
I for definition of groups .
in both ventricles . Comparing the group I patients (0 .01 to
0.04 ml/kg) at Baylor College of Medicine and University of
Chicago, the former patients achieved better opacification in
the right (90% to 100% versus 22% to 44%, respectively) and
left (30% to 60% versus 0% to I]% respectively) ventricle .
However, comparing the group II patients (0 .04 to 0.08
nillkg), those from the University of Chicago achieved
approximately equp! opacification of the right ventricle (80%
to 100% versus 90% to l00%, respectively) and better
opacification of the left ventricle (60% to 90% versus 60%n,
respectively) . Group III patients achieved similar opacifica-
tion of the right ventricle and 90% achieved +2 opacification
of the left ventricle at both institutions; however, group III
patients at Baylor College of Medicine achieved 70% of +2
opacification of the left ventricle using the dose of 0 .12
mUkg .
Protocol 2 (Table 5). In Patient 8, contrast was noted to
appear almost simultaneously in the right and left atria . An
intravenous infusion of hand-agitated saline solution re-
vealed the presence of contrast material in the left ventricle.
A presumptive diagnosis of a patent foramen ovate was
made and, therefore, the patient was excluded from the
efficacy analysis .
There was no difference in right ventricular opacification
between the solution containing the lower concentration of
microspheres (5 x tOs microspheresiml) and the solution
containing the higher concentration (8 x 10' microspheres/
ml) . Ninety percent of the subjects achieved at least +2
opacification of the right ventricle, beginning with the small-
est volume (0
.01 mtkg). In the left ventricle, however, there
was a difference between the two concentrations at a volume
of 0
.01 mllkg) (50% versus 70%) and 0 .04 mUkg (90% versus
100%)
. The higher doses (0 .04 mllkg) provided the best left
ventricular opacification and produced substantial attenua-
tion of the tight ventricular image presumably because of the
effects of acoustic shadowing.
Discussion
Safety
. This multicenter study represents the first clinical
evaluation of the safety and efficacy of a newly developed,
commercially prepared transpulmonary ultrasound contrast
agent (Albunex) . Previous studies (36) on the safety of
intravenous injections of hand-agitated agents have reported
a low incidence of complications
. Similarly, intraaortic and
intracoronary injections of both hand-agitated and sonicated
contrast agents have generally been found to be safe
(7,19,20,M-41) .
In the present study, no clinically significant
laboratory, ECG, physical or neurologic abnormalities were
detected after intravenous injections of the contrast agents .
A small number of reactions were noted, but were brief and
spontaneously resolved . Statistically significant changes in
vital signs were detected by analysis of variance
; however,
these were not recognized to be clinically significant
. Based
Before
Study
2 h After
1 jecdon
3 Days
After
Injection P Value
SBPtmm Hg)
134 ± 6 139
. 6 128 x 6
-30.001
DBP
(mm Hg) 82 * 5
80± 7 79 e 7 NS
HR (beats/min) 79 s 8
72 ± 10 79 * 12 NS
Rasp rate
(breaths/min)
12±2
12±0
.9 1131 .4
NS
Temp ('C) 36±0.3 36.6*_0.2 36.7±0 .2 NS
Volume of Albunex (m01rg)
Patient Group 0 .01 0 .02 0 .04 0.06 0.08 0 .10 0.12
University of Chicago
Right ventricle
Group 1' 22
22 44
Group 11 55 100
100
Group III Ira Ira
100
Left ventricle
Group I' 0 11 11
Group 11
60 80 90
Group 111 90 90 90
Baylor College of
Medicine
Right ventricle
(imp I 90 100 100
Group u 100 90 100
Group III Ira 100 100
14 Wrinkle
Group
1
30 30 60
Group 11 60 60 60
Group
111 90 90 70
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on these observations, it appears that intravenous
adminis-
tration of this ultrasound contrast agent is safe and that
additional clinical experience will be required
.
Quality of contrast effect. Previous studies (11,12,28-34)
have demonstrated the feasibility of trdnspulmonary passage
of echocardiographic contrast agents . In our study, protocol
I was designed to determine the volume of Albunex at a low
concentration required to opacify the left ventricle after
intravenous injections
. At both The University of Chicago
a :d Baylor College of Medicine, the use of 0.01 to 0.04 mt/kg
was inadequate for left ventricular opacification in the ma-
jority of the patients . Increasing the volume to 0.04 to 0 .08
mllkg resulted in +2 opacification it . 60% to 90% of patients
at The University of Chicago and 60% at Baylor College
of
Medicine . Interestingly, among patients receiving the low
volume dose of Albunex, a higher percent at Baylor College
of Medicine than at The University of Chicago achieved +2
opacification of both ventricles . Conversely, for the 0 .04 to
0 .08 ml/kg dose, patients at The University of Chicago
achieved a greater percent of opacification than
did those at
Baylor College of Medicine .
The apparent differences in contrast opac((cation
ob-
served at the two institutions may be explained by any of the
following characteristics . 1. Small sample size . The individ-
Table S. Percent of the 10 Patients in Protocol 2 Having
a Grade +2 Cavity Opacificatinn
Data are the mean
-1-
dete
.mined by two blinded observers .
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Volume of Albunex (mllkg)
Figure 2. Serial frames from a single intravenous injection in a
patient whose heart was irraged from an apical four chamber view.
A, Baseline image witoutcontrast ; 3, early image showing contrast
in the right ventricle; C, contrast opacification of both left Bad right
ventricles
. In these images, the left atrium and left ventricle IV) are
on the left and the right atrium and right ventricle (RV) are on the
right .
oat group sample sizes were small (n = 10) and the variations
between the groups may
be due in part to chance .
2 . Subjectivity of opacifcaion grade. The grading system
used (0 to +3 scale) was subjective and relied on the
judgment of the independent observers.
3 . Differences between the patient groups .
No attempt
was made to ensure that the patient groups were equivalent
with respect to age, weight, gender, ethnic origin and so on .
Notably the patients in group II from Baylor College of
Medicine were significantly older than the group If patients
from The University of Chicago. Other differences such as
smoking history or minor pulmonary disease could have
influenced the degree of opacification .
4 . Differences in pulmonary vascularphysiology . Patients
received volumes of Albunex based on their body mass.
Presumably, the pulmonary vasculature represents the
greatest impediment to passage of contrast material to the
left-sided cardiac chambers
. Because total pulmonary vas-
cular blood volume is proportional to body surface area
rather than mass (42), differences in patients' body habitus
may have affected transpulmonary passage of the contrast
agent .
5 . Differences in injection technique. During the studies,
patient position (decubitus or supine) was noted to influence
the rate of contrast appearance in the right heart chambers
after injection . Similarly, differences in the vein placement
of the angiocatheter may have influenced the results, as
might the rate of Albunex administration (estimated
to
be 0.5
to 1 .0 ml/s) .
0.01 0 .02 0 .04
Right ventricle
5
x
10e
mierosphereslml
90 Im 100
8
x lop microspheres/ml 90 100 100
Len
ventricle
5 x lox micmspheres/ml 50 so
90
8 x tae mineospheres/od 70 90 1m
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6. Contrast agent variability. During the studies, Albunex
solutions from different lot numbers were provided to the
investigators by the manufacturer. The investigators did not
perform
an analysis of contrast agent uniformity. Any vari-
ability in microsphere concentration or size could have
influenced the degree of cavity opacification .
Despite these differences, +2 or +3 left ventricular
opacification was achieved in the majority of patients in
groups U and 111 (0.4 to 1.2 mUkg). Further studies will be
required to determine to what extent variables (volume,
body mass, pulmonary disease, injection technique, agent
consistency and so on) affect left ventricular opacification in
patients.
Protocol 2 differed from protocol I in that the subjects
were healthy volunteers and Albunex solutions containing
two different concentrations of microspheres were adminis-
tered. At the lower concentration, patients at the Thorax-
center revealed higher degrees of opacification for the same
dose schedule than did group I patients at the other two
institutions . This difference may have been due to the
characteristics of the Thoraxcenter study group, which
included significantly younger. lager and lighter patients
than their group I counterparts at The University of Chicago
and Baylor College of Medicine, perhaps resulting in better
image quality. Improved opacification was observed in pro
.
toool2 with the higher concentrations of microspheres . Our
results suggest that both the volume injected and the con-
centration of microspheres play a major role in the degree of
cavity opacification . The higher degree of right ventricular
opacificaton and its frequent attenuation suggest that the
volume and concentration needed to study the right ventricle
might differ from that needed to study the left ventricle
.
The in vitro stability of Albunex has been reported (Mo-
lecular Biosystems communication) to be >95% retention at
8 months, which differs significantly from the persistence of
ideal gas bubbles such as those of sonicated Renografrn-76
(10). Although sonicated Renografin-76 microbubbles disap-
pear rapidly by diffusion, the fate
of albumin microspheres
appears to result in trapping, primarily in the liver, spleen
and reticulDendothelial system, and is dependent on the size
of the microspheres (43) . The size of Albunex microspheres
is sufficiently small that they can pass through the pulmonary
circulation to opacify the left ventricle . In the present study,
the contrast agent was administered as an
intravenous bolus
injection . However, by the time the contrast agent reached
the right ventricle, it was mixed with blood and no longer
passed as a discrete bolus . For a 70 kg subject receiving an
Albuncx volume of 0.04 mIkg with a concentration of
8 x 100
microsphereslml, the ultimate concentration after
mixing with the entire blood volume (5 liters) would
be
approximately 5 X 10 3 microspheres per ml of blood. This
concentration results in a visible attenuation in the ultra-
sound backscatter intensity and presumably accounts for the
image attenuation seen in the right ventricle . In the left
ventricle, however, no visible attenuation of signal was
observed during peak opacification . Therefore, the micro-
sphere concentration may be assumed to be significantly
lower than that observed in the right ventricle . This loss of
contrast effect cannot be explained by trapping in the lungs
(de long et al ., unpublished observations). Therefore, the
effects of dilution, cyclic pressure variation or microsphere
dissolution may contribute to the loss of contrast effect
.
Further investigation is required to determine precisely the
fate of the microspheres and the physical factors affecting
transpulmonary opacification.
Potential clinical applications . Several potential clinical
applications for a stabilized ultrasound contrast agent capa-
ble of reliable transpulmonary passage exist.
I. Assessment of left ventricle function. A recognized
limitation of echocardiography in the evaluation of global
and regional wall motion derives from endocardial border
identification in some patients. Because of the ease of
intravenous administration of the contrast agent, the ability
of left ventricular contrast medium to enhance edge detec-
tion may prove to
be useful in detecting wall motion abnor-
malities in the acute setting and during stress echocardiog-
raphy (44-46). With opacification provided through the use
of this agent, it may be possible to calculate cardiac output
or left ventricular ejection fraction using time-intensity var-
iables in a method analogous to radionuclide studies
.
2
. Quanritation of valvular regurgitation. Doppler color
flow mapping is currently used to assess mitral and aortic
regurgitation . However, the method is velocity rather than
volume dependent and is often poorly reproducible (47). It is
conceivable that videodensitometric analysis of the regur-
gitant contrast effect could provide a method of evaluating
the degree of valvular regurgitation .
3. Improved detection of intraventrieular flow patterns
.
Left ventricular contrast studies may be useful for assessing
abnormal intraventricular flow patterns in ischemic heart
disease. A recent study by Beppu et al. (46) suggests that in
a canine model of experimental myocardial inlbretion, echo-
cardiographic contrast medium can assist in assessing blood
flow pathways that may lead to thrombus formation
. Echo-
cardiographic detection of clots or aneurysms may also
be
significantly improved . Early reports (45,48) have com-
mented on the enhancement of the Doppler signal after
contrast appearance.
4
. Perfusion assessment. Myocardial contrast echocar-
diography has been shown (7,19,20,37-41) to be a useful
clinical technique fordefiningregonal myocardial perfusion
.
Until now, echocardiographic contrast studies in patients
were performed during cardiac catheterization or in the
operating room because transpulmonary opacification of the
myocardium was not routinely feasible . A preliminary report
of a videodensiometric analysis of the patients studied in
protocol 2 (Thoraxcenter) by Silverman et al . (49) described
the enhancement of myocardial backscatler after intrave-
JACC Vol. 16, No . 2
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nous irgections of Albunex . The ability of sonicated albumin
to cross the pulmonary barrier and the anticipated improve-
ments in digital acquisition of ultrasound signals from units
with expanded dynamic range and direct radiofrequency
data acquisition (41) may provide the ability to quantitate
myocardial perfusion after the intravenous administration of
contrast material. If successful, this technique may eventu-
ally play a significant role in the diagnosis,
evaluation and
clinical management of patients with ischemic heart disease .
CoieWmom . The present multicenter study is the first
report on the clinical use of a commercially prepared ultra-
sound contrast agent (Albunex), In 71 patients who were
either normotensive or mildly hypertensive, no significant
adverse physical, neurologic, ECG or laboratory sequelae
were detected.
The data also demonstrated the feasibility and r rroduc-
ibility
of left ventricular opacification after intravenous in-
jections of this agent
. However, several important questions
are raised by the results
of this study. What is the optimal
dose determination? Should the volume be administered on
the basis of
body mass or another variable such as body
surface area? What arc the effects of injection technique and
rate on ventricular opacification. What is the fate of the
microspheres in the circulation and what factors affect their
disappearance? Does a sufficient concentration of micro-
spheres enter the coronary circulation to increase myocar-
dial backscatter enough to assess myocardial perfusion with
commercial ultrasound equipment? These questions will
require additional experience with this agent and the use of
sophisticated quantitative imaging and analysis .
On the basis of the data presented, intravenous injection
of Albunex appears to be a safe and effective method for
providing left ventricular ultrasound contrast opacification .
A
standardized
ultrasound contrast agent appears to be a
major advance in the field of contrast echocardiography .
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